Magnetic brain stimulation for adults with fibromyalgia pain
Tests magnetic stimulation of the front brain in adults with fibromyalgia.
Key facts
- Who runs it
- Duke University
- Where
- Durham, United StatesSee the site
- Trial code
- Registry title
- Pain & Reward Neuromodulation of CNS Circuits
- Status
- Enrolling by invitation
- People taking part
- 30 people, planned
- Started
- 21 Jul 2026
- Expected to end
- Jun 2027
- Type of study
- Interventional
- Treatments tested
- Transcranial Magnetic Stimulation (TMS)
- Record updated
- 28 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adult women with fibromyalgia to test transcranial magnetic stimulation (TMS), a magnetic pulse treatment aimed at the front of the brain. Participants have MRI scans, TMS sessions over 4 days and questionnaires.
- Age
- 18 years and older
- Sex
- Women only. Female sex at birth and currently female.
- Disease stage
- Primary fibromyalgia syndrome, diagnosed and confirmed by a physician.
- Earlier treatment
- No opioid medicines in the previous 90 days, and no more than a 30-day period of opioid use in a lifetime. Prescribed medicine doses and any psychotherapy must stay the same during the study. No change in psychiatric medicines in the prior 2 months.
Main reasons for not taking part
- Cannot have an MRI, for example metal implants, fear of closed spaces, pregnancy or planning pregnancy.
- Cannot have TMS, for example a history of seizures or epilepsy, stroke, brain surgery, head injury or implanted devices like a pacemaker.
- Current hypomania, psychotic disorder, Bipolar I disorder, or moderate or severe alcohol or substance use disorder.
- Current serious medical illness, including severe migraine headaches.
- Use of an experimental drug or device within 4 weeks of screening.
The registry criteria, word for word
Show all 24 criteriaShow less
Other criteria
- Inclusions:
- Female and ages 18 +
- Ability to read/understand English and give consent to participate
- Physician diagnosis \& confirmation of primary fibromyalgia syndrome
- Verbal agreement to maintain dose of prescribed medication (if any) constant throughout the study, except exclusion medication and except if there is a medical emergency requiring changes in medication
- If enrolled in psychotherapy, verbal agreement to maintain (not change or stop) the psychotherapy during the study
- Absence of use of opioid medications (during the previous 90 days, and no greater than a 30-day period during lifetime); Exclusions:
- limited ability to participate fully in behavioral tasks, longitudinal follow-up (e.g., plans to move out-of-state within 3 months)
- MRI contraindication (e.g., metal implants, claustrophobia, pregnant or planning to become pregnant)
- any factors that at the discretion of the investigators would adversely affect the participant or the integrity of the study (e.g., ongoing legal action or disability claim regarding pain, uncontrolled psychiatric disorder, head/neck injury, use of certain medications)
- male *; TMS-Specific Exclusions:
- TMS contraindication (e.g., history of seizures, medications contraindicated for risks/efficacy of TMS procedures)
- current hypomania,
- meets diagnostic criteria for current psychotic disorder, or psychotic features,
- meets diagnostic criteria for Bipolar I disorder,
- meets diagnostic criteria for current alcohol or substance use disorder (moderate and high severity)
- current uncontrolled anorexia or other condition requiring hospitalization,
- current serious medical illness, including current severe migraine headaches,
- changed psychotropic medications in the prior 2 months, or plans to change medication during the study,
- history of seizure except those therapeutically induced by ECT (childhood febrile seizures are acceptable and these subjects may be included in the study), history of epilepsy in self or first degree relatives, stroke, brain surgery, head injury, cranial metal implants, known structural brain lesion, devices that may be affected by TMS (pacemaker, medication pump, cochlear implant, implanted brain stimulator),
- conditions associated with increased intracranial pressure, space occupying brain lesion, transient ischemic attack, cerebral aneurysm, dementia, Parkinson's or Huntington's disease, multiple sclerosis,
- use of investigational drug or devices within 4 weeks of screening,
- cochlear implants,
- pregnancy; Only females will be enrolled in this study because it focuses on patients who have fibromyalgia which is more prevalent (both diagnosed and self-reported) in females; Due to the contributions of hormones to the conditions under study in this project, female eligibility in this study will be defined as an individual who is female sex at birth and currently female sex
Where in United States
- Duke University Medical CenterDurham, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
This pilot feasibility study aims to evaluate transcranial magnetic stimulation (TMS) targeting the prefrontal cortex in patients with fibromyalgia syndrome (FMS). The study will assess preliminary efficacy and mechanisms of central nervous system changes using neuroimaging, behavioral tasks, sensory testing, and neuroimmune markers. Participants will undergo MRI scans, multi-day TMS sessions, and complete questionnaires. The goal is to generate pilot data for future trials on neuromodulation for chronic pain.
The group in the trial
- Active TMSTreatment being tested
Participants receive TMS over 4 consecutive days (20 sessions total).
Treatment: Transcranial Magnetic Stimulation (TMS)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Pain & Reward Neuromodulation of CNS Circuits
- Plain-language title
- Magnetic brain stimulation for adults with fibromyalgia painGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 28 July 2026